Is Temozolomide on the market?

Temozolomide was approved by the U.S. Food and Drug Administration (FDA) in August 1999 as an oral capsule and subsequently as an intravenous injection in February 2009. It is currently marketed by Merck under the trademark TEMODAR. Temozolomide is an anticancer drug used to treat brain tumors such as glioblastoma and anaplastic astrocytoma.

Temozolomide was approved by the European Medicines Agency (EMA) in 1999 and is sold under the trade name TEMODAL for the treatment of malignant gliomas (brain tumors) in the following patient groups: newly diagnosed glioblastoma multiforme (an aggressive Temozolomide is used first with radiation therapy and then alone in adults and children aged three years and older who have malignant gliomas (such as glioblastoma multiforme or anaplastic astrocytoma) whose tumors have recurred or worsened after standard treatment.

The original drug temozolomide was approved by the State Food and Drug Administration in 2018 and entered the scope of Class B medical insurance through the relevant regulations of the National Medical Insurance Bureau. The price of a common specification of 100mg*1 tablet*5 bags per box may be around 2,000 yuan. The price of generic temozolomide drugs marketed overseas is relatively low, and its pharmaceutical ingredients are basically the same as those of the original temozolomide drug. For example, the price of a box of 100mg*5 produced by a Bangladeshi pharmaceutical factory may be around a few hundred yuan (the price may fluctuate due to exchange rates).